A multi-center, randomized, double-blind phase II trial of FOLFIRI + regorafenib or placebo for patients with metastatic colorectal cancer who failed one prior line of oxaliplatin-containing therapy

医学 瑞戈非尼 贝伐单抗 临床终点 福尔菲里 内科学 奥沙利铂 安慰剂 结直肠癌 肿瘤科 无进展生存期 外科 化疗 随机对照试验 癌症 病理 替代医学
作者
Bert H. O’Neil,Séamus O’Reilly,Samer S. Kasbari,R. Kim,Ray McDermott,David Moore,William Grogan,Allen Lee Cohn,Tanios Bekaii‐Saab,Anastasia Ivanova,Olugbenga Olowokure,N. Fernando,John McCaffrey,Bassel F. El‐Rayes,Anne M. Horgan,Thomas M. Ryan,Gary B. Sherrill,Ghaith Al Yacoub,Richard M. Goldberg,Hanna K. Sanoff
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:27: vi153-vi153 被引量:6
标识
DOI:10.1093/annonc/mdw370.13
摘要

Regorafenib (rego) is a multi-kinase inhibitor that inhibits angiogenesis (VEGFR 2/3, TIE-2), and growth and proliferation (BRAF), and is active in chemotherapy-refractory mCRC. This international investigator-initiated trial assessed the efficacy of second-line FOLFIRI +/- rego given on an intermittent dosing strategy (week on, week off) in patients with mCRC. Patients with mCRC were recruited from 45 sites in the US and Ireland (ICORG). Key eligibility included progression on first-line OX and fluoropyrimidine, measurable disease, ECOG PS 0-1, and adequate organ function. Patients were randomized 2:1 (double blind), stratified by prior bevacizumab, to receive rego 160 mg (arm A) or placebo (arm B) on days 4-10 and 18-24 with FOLFIRI given on days 1-2 and 15-16 of every 28 day cycle. Treatment was continued until progression or toxicity. The primary endpoint was PFS; secondary endpoints included RR (CR + PR) and OS. With n = 180 (120 A, 60 B) 75% event rate yielded 135 events required to achieve 90% power for a 60% improvement in PFS with a one-sided alpha of 0.1. 181 patients were enrolled from 4/11 to 8/15 (120 rego, 61 placebo). Arms were balanced for age, sex, prior adjuvant, prior bev. 118 (65.2%) had prior anti-VEGF, 14 (7.7%) had prior anti-EGFR in 1stline (2 patients received both). Median PFS was 6.14 mo for arm A and 5.29 mo for arm B, (HR 0.69, log-rank p = 0.02). Median OS was 13.2 mo for A and 12.0 mo for B (HR 1.06, p = 0.76). RR in evaluable pts was 32% (95% CI 23, 42) for A, 19% (95% CI 10, 32) for B, p = 0.10. RR in ITT population was 27% versus 18% (p = 0.11). Grade ≥ 3 adverse events occurring in > 5% of pts (A v. B) included neutropenia (40% v. 30%), diarrhea (14% v. 5%), hypophosphatemia (14% v 0), fatigue (11% v. 7%), mucositis (9% v. 10%), HTN (8% v. 2%), elevated lipase (8% v. 3%). Hand-foot syndrome grade ≥ was 5% on arm A vs 2% on B. The addition of rego on an intermittent schedule to FOLFIRI was tolerable, and resulted in a statistically significant prolongation of PFS compared to FOLFIRI alone. The study was underpowered to definitively evaluate OS, and potentially influenced by post-protocol crossover to regorafenib.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
bkagyin应助宋宋宋2采纳,获得10
刚刚
0911wxt发布了新的文献求助10
1秒前
2秒前
怕黑不惜发布了新的文献求助50
3秒前
sxy发布了新的文献求助10
3秒前
4秒前
zhou应助直率谷蕊采纳,获得10
4秒前
bean完成签到 ,获得积分10
9秒前
zhou发布了新的文献求助10
9秒前
jessica完成签到,获得积分20
9秒前
独特冰安发布了新的文献求助10
9秒前
10秒前
斯文雪青完成签到,获得积分10
10秒前
11秒前
11秒前
ICY完成签到,获得积分10
12秒前
13秒前
阿朱完成签到,获得积分20
13秒前
15秒前
Yangyang发布了新的文献求助200
16秒前
16秒前
姜雪发布了新的文献求助30
16秒前
量子星尘发布了新的文献求助10
18秒前
绿茶很茶哈哈哈完成签到,获得积分10
19秒前
20秒前
123完成签到,获得积分20
21秒前
Z可发布了新的文献求助10
21秒前
领导范儿应助戴佳伟彩笔采纳,获得10
22秒前
linli完成签到,获得积分10
23秒前
勤恳的依霜完成签到,获得积分10
23秒前
yy完成签到,获得积分10
23秒前
123发布了新的文献求助10
23秒前
24秒前
24秒前
伶俐一曲发布了新的文献求助10
26秒前
xiaowei完成签到,获得积分20
26秒前
27秒前
29秒前
wanci应助wan采纳,获得10
29秒前
怡然的晓丝完成签到 ,获得积分10
30秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975426
求助须知:如何正确求助?哪些是违规求助? 3519848
关于积分的说明 11199831
捐赠科研通 3256122
什么是DOI,文献DOI怎么找? 1798124
邀请新用户注册赠送积分活动 877386
科研通“疑难数据库(出版商)”最低求助积分说明 806305